Baillie Gifford & Co, an independent investment management firm, released its third-quarter 2026 investor letter for “US Equity Growth Strategy”. The letter can be downloaded here. While AI safety and ...

Few large biotech stocks have rewarded patience like Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the size of that run ...

After a few years of stagnation, this stock is soaring.

Moderna (MRNA) stock has returned 621% over the past twelve months, easily outpacing the S&P 500's 17.0% return. Yet the ...

Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a Covid vaccine company.

Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has ...

Moderna shares gained 18% last week—finishing it at their highest level in more than four years—after the New York Times ...

Following last month's super rally, a growing number of analysts are now calling for caution.

Moderna stock rallied by triple digits on Aug. 19 with positive news for its cancer vaccine. Is mRNA ready to return to the ...

Moderna ( MRNA) rose roughly 5% and Eli Lilly ( LLY) added nearly 3% to rank among the day’s best-performing stocks in the ...

Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.

The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before investors pulled back.